bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: A J J M A M F J
2013: D N O S A

 
  Other news for:
Diabetes Mellitus
Diabetes Mellitus, Non-Insulin-Dependent
Lipoproteins, HDL Cholesterol
Hormones
Obesity
Weight Loss
 Resources from HONselect
New Drug Shows Promise for Type 2 Diabetes
It appears to improve blood fat levels and may aid weight loss, researchers report

By Brenda Goodman
HealthDay Reporter

TUESDAY, Sept. 3 (HealthDay News) -- An injectable drug that mimics the action of a little-known hormone may hold promise for patients with type 2 diabetes.

The experimental drug, called LY, is a copy of a hormone called fibroblast growth factor 21 (FGF21), and researchers report that it seems to help protect against obesity and may boost the action of insulin.

In a month-long trial of 46 patients with type 2 diabetes who were randomly assigned to receive daily injections of the drug or an inactive placebo, patients who received the highest doses of the drug saw significant, favorable changes in their blood fat (lipid) levels compared to those on the dummy shots. Two "bad" blood fats -- LDL and triglycerides -- dropped, while patients' HDL, or "good" cholesterol, increased. Total cholesterol counts also dropped significantly compared to placebo shots.

Patients on the highest doses of the drug also lost a bit of weight, the researchers added.

Insulin and blood sugar levels did dip a bit in patients on the highest doses of the drug, but those changes were not statistically significant compared to patients who were taking the placebo shots, which means they could simply have been a coincidence.

Still, the study authors said they were hopeful that the drug may one day become a useful addition to currently available therapies.

"Our current understanding suggests that FGF21 has the ability to favorably affect body weight, partially normalize abnormal lipid levels in patients with diabetes, and has the potential to improve glycemic control," said senior study author Dr. Dave Moller, vice president of endocrinology and cardiovascular research, and clinical investigation for Eli Lilly Co., the company that's developing the drug.

"These are substantial issues and unmet medical needs for patients with obesity and type 2 diabetes," he added.

The study is published in the Sept. 3 issue of the journal Cell Metabolism.

An endocrinologist who was not involved in the research said the effects of the experimental medication were intriguing.

"There are some interesting properties here that longer studies and bigger numbers will need to confirm," said Dr. Ronald Goldberg, a professor of medicine in the Diabetes Research Institute at the University of Miami's Miller School of Medicine. "This is early days for this new medication."

Goldberg said a longer study would be needed to see if the changes in blood fat levels and weight amounted to real benefits for patients with diabetes, such as a reduction in heart attacks or other complications of the disease.

So far, other drugs that raise good cholesterol and lower triglycerides have not demonstrated real benefits for patients.

And side effects could be a concern. Even though the study was short, there were some signs that the medication might not be well-tolerated, the report indicated.

One patient on the highest dose of the drug developed a serious allergic reaction to the medication including a drop in blood pressure, itching and hives, and had to be treated with corticosteroids and antihistamines.

While no other serious allergic reactions were reported, more than 80 percent of patients on the two highest doses of the drug developed antibodies to the protein, a sign that their body recognized the drug as foreign and was mounting an immune reaction against it, something that might diminish the effectiveness of the medication over time.

"That's definitely an issue," Goldberg said, adding that he thought scientists would probably try to tweak the drug to make it less likely to spur immune reactions.

More information

For more on cholesterol and diabetes, visit the American Heart Association.

SOURCES: David Moller, M.D., vice president, endocrinology and cardiovascular research and clinical investigation, Eli Lilly and Co., Indianapolis; Ronald Goldberg, M.D., professor, medicine, The Diabetes Research Institute, Miller School of Medicine, University of Miami; Sept. 3, 2013, Cell Metabolism

Copyright © 2013 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=679849

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Blood
Cholesterol
Research Personnel
Hormones
Hypersensitivity
Heart
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact